Skip to content

Ventricular Arrhythmias After Pulmonary Vein Isolation

A Single-center Observational Study to Examine the Occurrence of Ventricular Arrhythmias After Pulmonary Vein Isolation

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02699255
Enrollment
111
Registered
2016-03-04
Start date
2014-10-31
Completion date
2017-01-27
Last updated
2019-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Ventricular Arrhythmias

Brief summary

The investigators study aimed to observe the occurrence of new premature ventricular complexes and other ventricular arrhythmias after pulmonary vein isolation.

Detailed description

Atrial fibrillation is the most common arrhythmia with a lifetime risk for development of over 20%. Pulmonary vein isolation is now established as therapy of choice for patients with symptomatic atrial fibrillation. It is well known that this interventional therapy inevitably modulates the intracardiac autonomic nervous system. While this ablation might alter atrial electrophysiology beneficially, the impact on ventricular electrophysiology remains unclear.

Interventions

None listed

Sponsors

Universitätsklinikum Hamburg-Eppendorf
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Age \> 18 years * Paroxysmal atrial fibrillation scheduled to undergo pulmonary vein isolation

Exclusion criteria

* Age \< 18 years * Persistent atrial fibrillation * Life expectancy less than 12 months * Acute myocardial infarction, coronary artery bypass graft surgery, open heart surgery, or percutaneous transluminal coronary angioplasty within less than 3 months prior to inclusion * Documentation of \>30 premature ventricular complexes per hour, salvos or ventricular tachycardias prior to atrial fibrillation ablation

Design outcomes

Primary

MeasureTime frameDescription
Ventricular arrhythmiasone yearNumber of patients with premature ventricular complexes, ventricular tachycardias or ventricular fibrillation.

Secondary

MeasureTime frameDescription
Arrhythmia recurrenceone yearNumber of patients with premature ventricular complexes, ventricular tachycardias or ventricular fibrillation.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026